返回 
加入收藏
埃克替尼对比吉非替尼治疗EGFR突变型晚期NSCLC的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 埃克替尼对比吉非替尼治疗EGFR突变型晚期NSCLC的临床观察 |
| TITLE： | Clinical observation of icotinib versus gefitinib in the treatment of EGFR-mutated advanced non-small cell lung cancer |
| 摘要： | 目的 比较埃克替尼与吉非替尼治疗表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌（NSCLC）的疗效和安全性。方法回顾性分析2015年12月－2021年9月我院就诊的EGFR突变型晚期NSCLC患者资料146例，按用药的不同分为埃克替尼组（73例）和吉非替尼组（73例）。埃克替尼组患者单用盐酸埃克替尼片（125mg，每日3次，口服）或联合常规化疗；吉非替尼组患者单用吉非替尼片（0.25g，每日1次，口服）或联合常规化疗。观察两组患者的近期临床疗效、无进展生存期（PFS），采用Cox回归模型分析影响患者预后的因素，记录两组患者的不良反应发生情况。结果两组患者的客观缓解率，疾病控制率，1～2级、3～4级不良反应总发生率比较，差异均无统计学意义（P＞0.05）；埃克替尼组患者的中位PFS显著优于吉非替尼组（P＝0.048）。基于患者基本资料的PFS亚组分析结果显示，与吉非替尼组比较，埃克替尼组中女性[HR＝0.57，95%CI（0.34，0.96），P＝0.031]和非脑转移患者[HR＝0.58，95%CI（0.36，0.91），P＝0.017]的PFS显著延长。回归模型分析结果显示，EGFR19exonDel突变[HR＝0.50，95%CI（0.25，1.00），P＝0.049]、EGFR21exonL858R突变[HR＝0.44，95%CI（0.21，0.89），P＝0.022]和埃克替尼治疗[HR＝0.65，95%CI（0.44，0.96），P＝0.030]为影响患者预后的因素。结论埃克替尼与吉非替尼治疗EGFR突变型晚期NSCLC的近期临床疗效和安全性均相当，但埃克替尼可以显著延长患者的PFS；EGFR19exonDel和EGFR21exonL858R突变及接受埃克替尼治疗是影响患者预后的因素。 |
| ABSTRACT： | OBJECTIVE To compare the efficacy and safety of icotinib and gefitinib in the treatment of epidermal growth factor receptor （EGFR）-mutated advanced non-small cell lung cancer （NSCLC）. METHODS The data of 146 patients with EGFR- mutant advanced NSCLC of our Hospital from December 2015 to September 2021 were retrospectively analyzed and divided into the gefitinib group （73 cases） and the icotinib group （73 cases） according to the drug use. Patients in the gefitinib group were given 0.25 g of gefitinib tablets once a day orally by single drug or combined with conventional chemotherapy， while patients in the icotinib group were given 125 mg of icotinib hydrochloride tablets three times a day orally by single drug or combined with conventional chemotherapy. Short-term efficacy， progression-free survival （PFS） were observed； Cox regression model was used to analyze the factors affecting the prognosis of patients； the occurrence of ADR were observed in the two groups. RESULTS There was no statistically significant difference in the objective remission rate， disease control rate， and the incidence of grade 1-2 and grade 3-4 adverse drug reactions between the two groups （P＞0.05）； median PFS was significantly better in the icotinib group than in the gefitinib group （P＝0.048）. Results of subgroup analysis based on patients basic information showed that compared with the gefitinib group， PFS of female [HR＝0.57，95%CI（0.34，0.96），P＝0.031] and non-brain metastatic patients [HR＝0.58，95%CI（0.36，0.91），P＝0.017] in icotinib group were prolonged significantly. Results of regression model analysis showed that EGFR19 exon Del mutation [HR＝0.50， 95%CI（0.25，1.00）， P＝0.049]， EGFR21 exon L858R mutation [HR＝0.44， 95%CI（0.21，0.89）， P＝0.022] and icotinib treatment [HR＝0.65， 95%CI （0.44，0.96）， P＝0.030] were influential factors for prognosis. CONCLUSIONS The short-term efficacy and safety of icotinib and gefitinib in the treatment of EGFR- mutant advanced NSCLC are comparable， but icotinib can significantly prolong the patients’ PFS； EGFR19 exon Del， EGFR21 exon L858R mutations and icotinib treatment are factors affecting patients’ prognosis. |
| 期刊： | 2023年第34卷第10期 |
| 作者： | 吴方雨；陈卫东；夏盼盼；张旭东；沈爱宗 |
| AUTHORS： | WU Fangyu，CHEN Weidong，XIA Panpan，ZHANG Xudong，SHEN Aizong |
| 关键字： | 吉非替尼；埃克替尼；表皮生长因子受体突变；晚期非小细胞肺癌；疗效；安全性 |
| KEYWORDS： | gefitinib； icotinib； EGFR mutation； advanced non-small cell lung cancer； efficacy； safety |
| 阅读数： | 189 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
